PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYUREA FOR USE IN THE TREATMENT OF SEVERE CHRONIC ANEMIA
The invention relates to a pharmaceutical composition containing hydroxyurea, for the treatment of severe chronic anemia in a patient suffering from sickle cell anemia not already undergoing treatment with hydroxyurea and not suffering a vaso-occlusive crisis.
1 . A pharmaceutical composition comprising hydroxyurea as an active substance, for use in the treatment of severe chronic anaemia in a patient suffering from sickle cell disease and not having vaso-occlusive crisis, the total haemoglobin level in said patient being, before said use of hydroxyurea, less than or equal to 7.5 g/dl of blood.
2 . The pharmaceutical composition for use according to claim 1 , for increasing the total haemoglobin level in said patient.
3 . The pharmaceutical composition for use according to claim 1 , wherein the total haemoglobin level in the patient, before use of hydroxyurea, is less than 7.4; 7.3; 7.2; 7.1; 7.0; 6.9; 6.8; 6.7; 6.6; 6.5; 6.4; 6.3; 6.2; 6.1 or 6.0 g/dl of blood.
4 . The pharmaceutical composition for use according to claim 1 , wherein the fetal haemoglobin level is between 5 and 25% of the total haemoglobin level in the patient, before use of hydroxyurea, in particular between 5 and 10% of the total haemoglobin level in the patient, or between 10 and 25% of the total haemoglobin level in the patient.
5 . The pharmaceutical composition for use according to claim 1 , wherein the patient is aged, before use of hydroxyurea, of 9 months or more, in particular of 2 years or more, the patient being in particular an adult, or aged of 1 to 18 years old, more particularly of 3 to 13 years old.
6 . The pharmaceutical composition for use according to claim 1 , wherein the total haemoglobin level in the patient increases by more than 9%, in particular after 6 to 18 months of hydroxyurea use, in particular by more than 13%, in particular after 12 to 24 months of hydroxyurea use.
7 . The pharmaceutical composition for use according to claim 1 , wherein the total haemoglobin level in the patient increases to more than 8.0 g/dl of blood, in particular after 12 to 24 months of hydroxyurea use.
8 . The pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition comprises hydroxyurea in an amount of from 50 to 1000 mg.
9 . The pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is a tablet, in particular a rapidly disintegrating tablet or a dispersible film-coated tablet, or a liquid pharmaceutical form such as a syrup or a drinkable solution.